DDInter1281 DDInter1376
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Neratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Colchicine
Neratinib may lead to a major life threatening interaction when taken with Fedratinib